Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Xpeng Inc - ADR — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Xpeng Inc - ADR trades at $9.42 (market cap $9.24B). The key difference: Xpeng Inc - ADR is the larger of the two by market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Xpeng Inc - ADR for 81 Days on average.
| TVTX | XPEV | |
|---|---|---|
Market Cap | $4.88B | $9.24B |
Volume | 1,668,577 | 6,669,510 |
Sector | Health | Consumer Cyclical |
52-Week High | $67.52 | $28.07 |
52-Week Low | $26.79 | $9.25 |
Typical Hold Time | 0 Days | 81 Days |
Enterprise Value | $5.01B | $11.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
XPeng (XPEV) trades at $9.75, up 0.93% on the day, amid a bearish technical signal and mixed financial performance. The company reported strong revenue growth to $76.72 billion in 2025 (XPeng earnings report, 2025) but continues to post net losses, with a negative net income margin of -4.14%. Recent news highlights expansion into AI and robotics, including the launch of the G9L SUV and humanoid robot production, signaling strategic diversification beyond electric vehicles.
The investment outlook balances high growth potential against persistent profitability challenges. Analyst consensus is bullish with a $17.55 price target (MarketBeat, 2026), but risks include intense EV competition, macroeconomic pressures in China, and the capital-intensive nature of new technology ventures. Shareholder value hinges on achieving sustained profitability and successful execution of its Physical AI initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
